Seoul National University College of Veterinary Medicine Integrative Veterinary Medicine Research Center Prof. Baek Seung-joon's team
3-month IMMUNIES clinical trial on dogs with terminal breast and liver cancer
Decreases in blood urea nitrogen, creatinine, liver enzymes, white blood cells, and inflammatory markers
Administration of 'IMMUNIES' to dogs with terminal breast and liver cancer over a 3-month period showed decreases in blood urea nitrogen, creatinine, liver enzymes, white blood cells, and inflammatory markers. Notably, red blood cells and hematocrit levels returned to normal ranges, demonstrating significant effects.
The Seoul National University College of Veterinary Medicine Integrative Veterinary Medicine Center announced on the 24th that these findings from a clinical trial commissioned by Herb Medipharm Inc. (formerly Petcell Bio), the developer of IMMUNIES (product name 'PETMUNIES'), were published on the 6th in the international journal 'Journal of Applied Biological Chemistry (JABC)' under the title 'IMMUNIES, A Unique Polyherbal Extract, Exhibits Antiproliferative Activity and Improves Tumor-bearing Canine Patients.'
The research team explained that throughout the study period, IMMUNIES demonstrated excellent tolerability in clinical and biochemical tests and exhibited cancer antiproliferative activity that suppressed tumor growth, confirming stabilization of the cancer condition. Cell experiments also confirmed that it acts specifically on cancer cells only.
Changes in blood and urine test results in dogs administered IMMUNIES over 3 months
"IMMUNIES is a natural herb-based therapeutic product originally developed to treat immune-related diseases such as cancer and viruses in humans, and is registered with the US FDA NDC (equivalent to over-the-counter drugs in Korea) as an 'immunomodulator,'" said Prof. Baek Seung-joon of Seoul National University College of Veterinary Medicine. "In this study, through clinical trials on elderly dogs with terminal cancer, we confirmed that IMMUNIES improves immunity in terminal cancer patients and exhibits cancer antiproliferative activity. It also showed effects in preventing complications caused by cancer, so we expect it to be greatly helpful as a cancer treatment or adjunctive therapy for companion animals undergoing chemotherapy in the future."
"The elderly dogs with terminal cancer that participated in this clinical trial were patients who could barely eat and slept all day," said Prof. Oh Won-seok (also Director of Oh Won-seok Hwanggeum Animal Hospital), who co-conducted the research. "After taking IMMUNIES, their appetite gradually increased, they maintained their weight, and they became more active than before taking the medication, resulting in high guardian satisfaction. Currently, there are almost no therapeutic supplements that can be prescribed for elderly companion animals with terminal cancer who are nearly untreatable or struggling with palliative care. We expect IMMUNIES could become that alternative."
"IMMUNIES is a product with long-proven safety and efficacy in humans, and we plan to launch it in the market as an adjunctive cancer treatment for companion animals in the near future," said a Herb Medipharm Inc. representative.
Cancer is the number one cause of death in dogs and cats worldwide. Since cancer is particularly difficult to treat once diagnosed, the results of this animal clinical trial of a natural herb-based cancer treatment product conducted at Seoul National University College of Veterinary Medicine are significant in demonstrating considerable potential for integrative veterinary medicine and natural product-based therapies in future cancer treatment.
"We plan to conduct additional large-scale clinical trials with the company on dogs and cats with cancer to evaluate the efficacy and potential benefits of IMMUNIES, as well as quality of life for companion animal cancer patients and guardian satisfaction," Prof. Baek explained.
Source: MK Health (Medical Correspondent Lee Byung-moon)
Seoul National University College of Veterinary Medicine Integrative Veterinary Medicine Research Center Prof. Baek Seung-joon's team
3-month IMMUNIES clinical trial on dogs with terminal breast and liver cancer
Decreases in blood urea nitrogen, creatinine, liver enzymes, white blood cells, and inflammatory markers
Administration of 'IMMUNIES' to dogs with terminal breast and liver cancer over a 3-month period showed decreases in blood urea nitrogen, creatinine, liver enzymes, white blood cells, and inflammatory markers. Notably, red blood cells and hematocrit levels returned to normal ranges, demonstrating significant effects.
The Seoul National University College of Veterinary Medicine Integrative Veterinary Medicine Center announced on the 24th that these findings from a clinical trial commissioned by Herb Medipharm Inc. (formerly Petcell Bio), the developer of IMMUNIES (product name 'PETMUNIES'), were published on the 6th in the international journal 'Journal of Applied Biological Chemistry (JABC)' under the title 'IMMUNIES, A Unique Polyherbal Extract, Exhibits Antiproliferative Activity and Improves Tumor-bearing Canine Patients.'
The research team explained that throughout the study period, IMMUNIES demonstrated excellent tolerability in clinical and biochemical tests and exhibited cancer antiproliferative activity that suppressed tumor growth, confirming stabilization of the cancer condition. Cell experiments also confirmed that it acts specifically on cancer cells only.
"IMMUNIES is a natural herb-based therapeutic product originally developed to treat immune-related diseases such as cancer and viruses in humans, and is registered with the US FDA NDC (equivalent to over-the-counter drugs in Korea) as an 'immunomodulator,'" said Prof. Baek Seung-joon of Seoul National University College of Veterinary Medicine. "In this study, through clinical trials on elderly dogs with terminal cancer, we confirmed that IMMUNIES improves immunity in terminal cancer patients and exhibits cancer antiproliferative activity. It also showed effects in preventing complications caused by cancer, so we expect it to be greatly helpful as a cancer treatment or adjunctive therapy for companion animals undergoing chemotherapy in the future."
"The elderly dogs with terminal cancer that participated in this clinical trial were patients who could barely eat and slept all day," said Prof. Oh Won-seok (also Director of Oh Won-seok Hwanggeum Animal Hospital), who co-conducted the research. "After taking IMMUNIES, their appetite gradually increased, they maintained their weight, and they became more active than before taking the medication, resulting in high guardian satisfaction. Currently, there are almost no therapeutic supplements that can be prescribed for elderly companion animals with terminal cancer who are nearly untreatable or struggling with palliative care. We expect IMMUNIES could become that alternative."
"IMMUNIES is a product with long-proven safety and efficacy in humans, and we plan to launch it in the market as an adjunctive cancer treatment for companion animals in the near future," said a Herb Medipharm Inc. representative.
Cancer is the number one cause of death in dogs and cats worldwide. Since cancer is particularly difficult to treat once diagnosed, the results of this animal clinical trial of a natural herb-based cancer treatment product conducted at Seoul National University College of Veterinary Medicine are significant in demonstrating considerable potential for integrative veterinary medicine and natural product-based therapies in future cancer treatment.
"We plan to conduct additional large-scale clinical trials with the company on dogs and cats with cancer to evaluate the efficacy and potential benefits of IMMUNIES, as well as quality of life for companion animal cancer patients and guardian satisfaction," Prof. Baek explained.
Source: MK Health (Medical Correspondent Lee Byung-moon)